These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27789556)

  • 1. Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
    Vilahur G; Gutiérrez M; Casani L; Varela L; Capdevila A; Pons-Lladó G; Carreras F; Carlsson L; Hidalgo A; Badimon L
    Circulation; 2016 Nov; 134(22):1708-1719. PubMed ID: 27789556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
    Nanhwan MK; Ling S; Kodakandla M; Nylander S; Ye Y; Birnbaum Y
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2078-85. PubMed ID: 25012137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
    Ye Y; Birnbaum GD; Perez-Polo JR; Nanhwan MK; Nylander S; Birnbaum Y
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1805-14. PubMed ID: 26044583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs.
    Vilahur G; Gutiérrez M; Casani L; Lambert C; Mendieta G; Ben-Aicha S; Capdevila A; Pons-Lladó G; Carreras F; Carlsson L; Hidalgo A; Badimon L
    Cardiovasc Res; 2018 Dec; 114(14):1860-1870. PubMed ID: 30124783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
    Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
    Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
    Kim JS; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W; Jeong KH
    Int J Cardiol; 2017 Jul; 238():110-116. PubMed ID: 28342632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.
    Teng R; Carlson GF; Nylander S; Andersson TL
    J Thromb Haemost; 2016 Dec; 14(12):2342-2352. PubMed ID: 27653814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
    Li P; Yang Y; Chen T; Liu Y; Cao A; Liu J; Wang Z; Zhao X; Qin Y; Ma L
    Sci Rep; 2015 Sep; 5():13789. PubMed ID: 26350388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
    Yang XM; Liu Y; Cui L; Yang X; Liu Y; Tandon N; Kambayashi J; Downey JM; Cohen MV
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):251-62. PubMed ID: 23233653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.